other treatment – Communicable Diseases Research

Trends in Treatments for Multisystem Inflammatory Syndrome in Children (MIS-C), United States, February 2020 – July 2021

Article

Published on 2022-09-302022-11-15
Journal: Clinical Infectious Diseases: An Official Publicat [Category] SARS, 진단,

ESCMID COVID-19 guidelines: update on treatment for patients with mild/moderate disease

Mini review

Published on 2022-08-012022-10-05
Journal: Clinical microbiology and infection : the official [Category] 임상, 치료법, 치료제,

Response of COVID-19 vaccination in multiple sclerosis patients following disease-modifying therapies: A meta-analysis

질병 조절 요법 후 다발성 경화증 환자에서 COVID-19 예방 접종의 반응: 메타 분석

Meta-Analysis

Published on 2022-07-012022-09-11
Journal: EBioMedicine [Category] COVID19(2023년), SARS, 바이오마커, 유전자 메커니즘,

[키워드] addressed anti-CD20 anti-CD20 therapy anti-CD20 treatment association benefit booster dose CD20 cellular response Cochrane Library conducted COVID-19 COVID-19 vaccination COVID-19 vaccine COVID-19 vaccines Disease-modifying therapies Efficacy evaluate foundation humoral Humoral response IFN-β immune response literature medRxiv Meta-analysis Multiple multiple sclerosis natural no significant difference Odds ratio Odds ratios other treatment other treatments Patient random-effect receiving receptor required response response to vaccination risk SARS-CoV-2 vaccination SARS-CoV-2 vaccine SARS-CoV-2 vaccines Science Serologic response serological Shanghai significantly higher sphingosine sphingosine-1-phosphate suggested supported T-cell Response therapy Treatment vaccination was performed
[DOI] 10.1016/j.ebiom.2022.104102 PMC 바로가기 [Article Type] Meta-Analysis

Colchicine for COVID-19 in the community (PRINCIPLE): a randomised, controlled, adaptive platform trial

Randomized Controlled Trial

Published on 2022-06-302022-10-04
Journal: The British Journal of General Practice [Category] COVID19(2023년), SARS, 임상,

Overview of clinical outcome and therapeutic effectiveness of Favipiravir in patients with COVID-19 admitted to intensive care unit, Riyadh, Saudi Arabia

사우디아라비아 리야드의 중환자실에 입원한 COVID-19 환자에 대한 Favipiravir의 임상 결과 및 치료 효과 개요

Article

Published on 2022-04-012022-09-11
Journal: Journal of infection and public health [Category] COVID19(2023년), SARS, 임상, 진단, 치료제,

[키워드] acute respiratory distress acute respiratory distress syndrome age analyzed antivirals approved ARDS BMI body mass body mass index Chloroquine Clinical outcome collected Comorbidities Comorbidity complications conducted control group Corticosteroid cough COVID-19 COVID-19 patient COVID-19 vaccine Critically ill critically ill COVID-19 patients Critically ill patient critically ill patients cytokine Cytokine storm diabetes Diabetes Mellitus effective Effectiveness Efficacy Efficacy and safety enrolled enzyme Favipiravir Fever FIVE FVP group had no heart disease hospital hypertension ICU ICUs IMPROVE inhibit intensive care intensive care unit intensive care units ischemic heart disease Kingdom majority male management medications not effective other treatment other treatments overall mortality P-value pandemic Patient patients with COVID-19 Potential treatment Randomized Research respiratory distress Respiratory distress syndrome retrospective cohort study RNA RNA polymerase Saudi Arabia severe acute respiratory distress syndrome severe symptoms Shortness of breath statistically significant Symptom syndrome the cytokine storm the disease the mean therapeutic therapeutic efficacy therapy Tocilizumab two groups Viral viral infection viral infections viral replication with COVID-19
[DOI] 10.1016/j.jiph.2022.01.013 PMC 바로가기 [Article Type] Article

Third dose of SARS-CoV-2 vaccination in hemato-oncological patients and health care workers: immune responses and adverse events – a retrospective cohort study

혈액종양 환자 및 의료 종사자에 대한 SARS-CoV-2 백신 3차 접종: 면역 반응 및 부작용 - 후향적 코호트 연구

Article

Published on 2022-04-012022-09-11
Journal: European journal of cancer (Oxford, England : 1990 [Category] COVID19(2023년), SARS, 변종,

[키워드] Adverse adverse event adverse events Analysis anti-S anti-SARS-CoV-2 antibody antibody levels B cell Cancer Care CD19 CD19+ CD56 CD56+ Cell chills Community community hospital Control correlated COVID-19 decrease dose event fatigue follow-up study haematological malignancies haematological malignancy HCW Health Health care Health care worker hospital immune response increasingly Italy local pain longitudinal longitudinal analysis Lower malignancy NK cell oncology other treatment other treatments Patient Patients with cancer patients with haematological Peripheral blood Questionnaires receiving retrieved retrospective cohort study SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 infections SARS-CoV-2 vaccination second vaccination Side-effect solid tumour Spike protein therapy trials Tumours vaccination virus variant waning immunity
[DOI] 10.1016/j.ejca.2022.01.019 PMC 바로가기 [Article Type] Article

Anti-Spike IgG in multiple sclerosis patients after BNT162b2 vaccine: An exploratory case-control study in Italy

BNT162b2 백신 후 다발성 경화증 환자의 Anti-Spike IgG: 이탈리아의 탐색적 사례 대조 연구

Multicenter Study

Published on 2022-02-012022-09-11
Journal: Multiple sclerosis and related disorders [Category] COVID19(2023년), MERS, SARS, 진단, 치료기술,

[키워드] adverse event AEs analyzed anti-spike antibodies antibodies antibody blood sample Blood samples BNT162b2 case-control study Clinical efficacy collected Community Comparisons condition Control COVID-19 COVID-19 vaccine described detect Disease-modifying therapies enrolled evaluated exploratory first dose HCW HCWs healthcare worker IgG Immunosuppressant immunosuppressants implication interquartile range IQR Italy median median and interquartile range Mild mild to moderate moderate multicenter Multiple multiple sclerosis observation Ocrelizumab of BNT162b2 one patient other treatment other treatments Patient patients patients treated performed Pfizer Pfizer-BioNTech receive receiving reduce reduced reported resolved respond scrutiny serological response severity the vaccine therapy treated treated patient treated patients Treatment treatment group vaccination vaccine dose Vaccine, BNT162b2. Vaccines Wilcoxon-Mann-Whitney
[DOI] 10.1016/j.msard.2021.103415 PMC 바로가기 [Article Type] Multicenter Study

Outside any therapeutic trial prescription of hydroxychloroquine for hospitalized patients with covid-19 during the first wave of the pandemic: A national inquiry of prescription patterns among French hospitalists

전염병의 첫 번째 물결 동안 Covid-19를 가진 입원 환자를위한 Hydroxychloroquine의 치료 시험 처방 외부에서 프랑스 병원의 처방전 패턴에 대한 국가 조사

Research Article

Published on 2022-01-212022-09-10
Journal: PLoS ONE [Category] SARS, 신약개발, 치료제,

[키워드] 95% CI 95% confidence interval acute respiratory syndrome adjusted adjusted odds ratio determinant determinants Efficacy email evaluate Evidence-based medicine Factor First wave framework French HCQ hospital hospitalized patient Hydroxychloroquine IMPROVE in vitro activity Infectious disease Infectious diseases inquiry internal medicine material member Multivariate analysis National other treatment other treatments outcome pandemic Patient patients patients hospitalized Primary outcome profile raise respiratory Result retained SARS-CoV-2 secondary Secondary outcomes Severe acute respiratory syndrome Society submitted therapeutic therapeutic trial treat Trial
[DOI] 10.1371/journal.pone.0261843 PMC 바로가기 [Article Type] Research Article

Efficacy and Safety of COVID-19 Convalescent Plasma in Hospitalized Patients A Randomized Clinical Trial

Randomized Controlled Trial

Published on 2021-12-132022-10-04
Journal: JAMA Internal Medicine [Category] Fulltext, MERS, 임상,

[키워드] adjusted adjusted odds ratio adverse event age Analysis analyzed baseline benefit black CCP clinical clinical status clinically concomitant medications conducted convalescent plasma Corticosteroid COVID-19 CrI cumulative defined determine double-blind Efficacy enrolled Enrollment Exploratory analyses finding heterogeneity heterogenous high-titer CCP Hispanic hospital Hospitalized hospitalized patient Importance IMPROVE improvement invasive IQR less measure median age men Neutralizing titer noninvasive objective occurred other treatment outcome oxygen supplementation Oxygenation pandemic participant patients patients hospitalized patients with COVID-19 Placebo placebo recipient placebo-controlled trial Point posterior probability prespecified outcome Primary outcome randomization Randomized randomized clinical trial receiving recipient Registration Relevance Remdesivir reported required Result risk Safety SARS-CoV-2 scale secondary outcome serostatus setting Sex suggested supplemental oxygen symptom duration symptom onset transfusion reaction transfusion reactions Treatment Trial Volume WHO with COVID-19 World Health Organization
[DOI] 10.1001/jamainternmed.2021.6850 PMC 바로가기 [Article Type] Randomized Controlled Trial

Passive immune therapies: another tool against COVID-19

수동 면역 요법: COVID-19에 대한 또 다른 도구

Review

Published on 2021-12-102022-09-11
Journal: Hematology. American Society of Hematology. Educat [Category] SARS, 진단, 치료제,

[키워드] absence acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 approval benefit Casirivimab convalescent plasma coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 Emergency use Evidence fatal COVID-19 Globulin high risk hyperimmune hyperimmune globulin immune immune system Infection Japan lack Mild mild to moderate Mild to moderate COVID-19 Moderate COVID-19 monoclonal neutralizing monoclonal antibodies other treatment pandemic Passive Patient patient groups performed Prevent Regulatory required Research respiratory respiratory infections SARS-CoV-2 severe acute respiratory syndrome Coronavirus severe respiratory infections Therapies therapy treat Treatment United Kingdom
[DOI] 10.1182/hematology.2021000299 PMC 바로가기 [Article Type] Review